Navigation Links
New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role
Date:2/12/2009

Alzheimer's disease

Two thirds of all patients with dementia suffer from Alzheimer's disease. Estimates indicate that by 2010 our country will have more than 150,000 Alzheimer's patients. Alzheimer's is a disease that gradually destroys brain cells, with the result that the mental capacity of patients with Alzheimer's gradually declines. At first, memory begins to fail, but the patient's cognitive capabilities also deteriorate as the disease progresses. Today, this disease cannot yet be cured. Current medicines for Alzheimer's patients sustain the memory functions for a short time, but they are unable to stop the brain cells from dying off. At best, they are able to limit the loss of memory during the early phases of the disease.

The β-amyloid cascade

The brains of Alzheimer's patients typically show the presence of amyloid plaques, which are abnormal accumulations of a protein (β-amyloid) between the neurons. The sticky β-amyloid develops when the precursor protein (amyloid precursor protein or APP) is cut into pieces incorrectly.

GPR3: target for new medicine

Several years ago, Bart De Strooper and other researchers elucidated the way in which these plaques originate and discovered that secretases play a large role in this process. Now, under the direction of Bart De Strooper, and in collaboration with researchers from the biotech company Galapagos, Amantha Thathiah and her colleagues have investigated whether additional substances are also involved in the development of the plaques. Which is apparently the case: Galapagos has identified the GPR3 protein as a new player. The VIB researchers have been able to show − in vitro (in cells isolated and studied in the laboratory) as well as in vivo (in living animals − mice, in this instance) − that blocking GPR3 leads to reduction of the plaques.

Importance of this research

The GPR3 protein is an important target molecule for the eventual development of a new medicine against Alzheimer's disease. The majority of all of the medicines that are available in pharmacies − regardless of the disease that they work against − act on proteins of a specific type. GPR3 is one of these − which, at this time, cannot be said for any other protein implicated in Alzheimer's.

Further research and development of this medicine will be carried out by the Flemish biotechnology company Galapagos. It is possible that 'the cure for Alzheimer's' will never be able to restore a patient's memory − but, hopefully, the disorder can be arrested, saving as many brain cells as possible.


'/>"/>

Contact: Pieter Van Dooren
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New target for anti-flu drug development
3. Central targets may hinder wider waste management objectives
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UIC researchers find promising new targets for antibiotics
6. Targeting nerve growth factor may cure liver cancer
7. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
8. Linchpin gene may be useful target for new breast cancer therapies
9. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
10. Study reveals a key to blood vessel growth and possible drug target
11. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
(Date:6/22/2016)... , June 22, 2016  According to ... next generation sequencing (NGS) market include significant efforts ... smaller sequencers.  More accessible and affordable sequencers, say ... growing demand for consumables including sample prep materials.  ... Market for Sample Preparation for Next Generation Sequencing ...
Breaking Biology Technology: